Amgen Reclaims Rights From GSK To Grow In Ex-US Markets
This article was originally published in Scrip
Executive Summary
Amgen Inc. will reacquire ex-US rights to its cancer drug Vectibix (panitumumab) and bone drugs Prolia (denosumab) and Xgeva (denosumab) in 48 countries from GlaxoSmithKline PLC, which generated $111m in combined revenue from the products in 2014.